The clinical research industry is no longer debating whether to use AI, it’s figuring out how to scale it. Medidata’s second annual survey, conducted by Everest Group, reveals a widening gap between organizations that adopted AI early and everyone else. The impact is clear: those with 18+ months of experience report improvements in trial timelines (72.9%) and protocol deviation reduction (67.5%) while the broader industry trails behind. With 92% of respondents increasing AI investment and 82% expecting 2-3x returns, optimism around AI’s potential is strong across the board. The organizations that overcome scaling barriers now will be the ones who see meaningful results and set the pace moving forward.
What’s Inside the 2026 Report
The Early Adopter Advantage: See where experienced organizations are reporting above expectation results.
Where AI Delivers Today: Discover where AI is moving the needle, with 86.5% seeing improvements in high-volume, rules-based workflows.
Navigating Barriers to Scale: Learn the hurdles holding organizations back from enterprise-wide implementation, and what early adopters did to overcome them.
From Automation to Prediction: Gain insights on the move toward protocol simulation, virtual twins, and autonomous agents.
Download the report to see where the industry’s seeing AI impact and what it takes to close the scaling gap.
Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata's Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn.
ADC manufacturing is becoming more complex as payloads, conjugation, lyophilisation, containment, and scale-up reshape CMC strategy and commercial readiness.
FDA Expedited IND Pilot Targets Faster First-In-Human Trials
The FDA’s Expedited IND Pilot introduces rolling review and sponsor-QRI partnerships to accelerate Phase I first-in-human trials while retaining regulatory oversight.
